GSA Capital Partners LLP Makes New Investment in Caribou Biosciences, Inc. $CRBU

GSA Capital Partners LLP bought a new position in Caribou Biosciences, Inc. (NASDAQ:CRBU) during the second quarter, HoldingsChannel.com reports. The fund bought 463,416 shares of the company’s stock, valued at approximately $816,000.

Other hedge funds have also recently made changes to their positions in the company. Renaissance Technologies LLC grew its position in Caribou Biosciences by 58.0% in the first quarter. Renaissance Technologies LLC now owns 2,590,497 shares of the company’s stock worth $4,922,000 after acquiring an additional 950,640 shares in the last quarter. Man Group plc bought a new position in Caribou Biosciences during the fourth quarter valued at $58,000. Invesco Ltd. raised its stake in shares of Caribou Biosciences by 187.2% in the fourth quarter. Invesco Ltd. now owns 35,063 shares of the company’s stock valued at $56,000 after acquiring an additional 22,856 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Caribou Biosciences by 80.0% in the 4th quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock worth $39,000 after acquiring an additional 10,824 shares during the last quarter. Finally, Creative Planning bought a new stake in shares of Caribou Biosciences in the 2nd quarter worth about $25,000. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CRBU shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Caribou Biosciences in a report on Friday, July 17th. HC Wainwright raised their price objective on shares of Caribou Biosciences from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Finally, Bank of America dropped their target price on Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Caribou Biosciences Stock Down 0.6%

Shares of Caribou Biosciences stock opened at $1.56 on Wednesday. The stock’s fifty day moving average is $1.67 and its two-hundred day moving average is $1.84. Caribou Biosciences, Inc. has a 52 week low of $1.38 and a 52 week high of $3.54. The company has a market capitalization of $154.72 million, a PE ratio of -1.44 and a beta of 2.38.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.08. The business had revenue of $1.50 million during the quarter, compared to the consensus estimate of $2.28 million. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%. As a group, research analysts anticipate that Caribou Biosciences, Inc. will post -0.88 earnings per share for the current year.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.